10.15.26 -- A Sponsor's Guide To Smarter Viral Vector CDMO Partnerships

Smarter viral vector manufacturing starts with early alignment, realistic scaling, and collaboration. Strategy and transparency reduce risk, control costs, and keep timelines on patients.

View automated, high‑throughput BiTE screening in mammalian cells, enabling rapid discovery of efficacious variants through precise genomic integration and scalable workflows.

Choosing between centralized and hybrid CAR-T manufacturing models impacts scalability, logistics, and timelines. Centralized models maximize control, while hybrid networks reduce vein-to-vein times.

Generative AI is creating novel gene-editing proteins with greater precision and potency, expanding therapeutic possibilities while overcoming the limits of naturally evolved enzymes.